Pádraig Wright

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 642 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett et al. · The Lancet Neurology · 2020 · 490 citations · Full text

Medicine, Neurology, Pharmacotherapy +5

Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia

Pádraig Wright, Martin Birkett, S.R. David et al. · American Journal of Psychiatry · 2001 · 303 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Thomas Voit, Haluk Topaloğlu, Volker Straub et al. · The Lancet Neurology · 2014 · 295 citations

Medicine, Pharmacology, Pharmacotherapy +5

A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia

Alan Breier, Karena Meehan, Martin Birkett et al. · Archives of General Psychiatry · 2002 · 290 citations

Medicine, Pharmacotherapy, Psychiatry +17